US 12,000,831 B2 · Method and compositions for detecting an adenoma-adenocarcinoma transition in cancer

Abstract

Methods and kits for detecting alternating spatial expression of PTEN and, optionally, SMAD4, CD44, and/or TP53 in colonic tumors are described. The methods and kits are useful for identifying a cancer stem cell (CSC)-like zone within a colonic tumor, identifying an adenoma-adenocarcinoma (Ad-ACA) transition zone in a colorectal cancer (CRC) tumor, identifying a CRC tumor that contains high-grade adenoma and/or early adenocarcinoma regions, identifying CSCs in a CRC tumor, diagnosing a subject with high-grade colon adenoma and/or early adenocarcinoma, and determining the likelihood that a colonic tumor in a subject will undergo invasive transformation if left untreated.

Claims9

Dependent claims

A method for isolating an adenoma-adenocarcinoma (Ad-ACA) transition region in a colonic tumor, comprising:

a. contacting one or more tissue sections of a colonic tumor sample with an antibody that specifically binds to PTEN and an antibody that specifically binds to SMAD4,
b. detecting the presence or absence of an alternating spatial pattern of PTEN expression and an alternating spatial pattern of SMAD4 expression,
c. identifying the presence of an Ad-ACA transition region in the colonic tumor where the alternating spatial pattern of PTEN expression and the alternating spatial pattern of SMAD4 expression are detected, and
d. isolating the Ad-ACA transition region from the colonic tumor when the Ad-ACA transition region is present;
wherein the alternating spatial pattern of SMAD4 expression is inversely correlated with the alternating spatial pattern of PTEN expression.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/146,070Filed 11 Jan 2021 · continuation

Priority

28 Jan 2014

Published

US 2021/0255188 A119 Aug 2021

Granted

4 Jun 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

G01N 33/57535
For cancer: of the large intestine, e.g. colon, rectum or anus
C12Q 1/6886
For diseases caused by alterations of genetic material: for cancer
C12Q 2600/106
Oligonucleotides characterized by their use: pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/118
Oligonucleotides characterized by their use: prognosis of disease development

Family

Application61/932,543Us provisional application · filed 28 Jan 2014

PCT/US2015/013061Parent of this continuation · filed 27 Jan 2015

US 2021/0255188 A1Pre-grant publication · published 19 Aug 2021

Application15/113,891Parent of this continuation

US 10,890,587 B2Parent of this continuation

US 2016/0341730 A1Published application

US 12,000,831 B2This patent

From the US filing history. Foreign family members aren’t listed.

Method and compositions for detecting an adenoma-adenocarcinoma transition in cancer

Life of this patent

Method and compositions for detecting an adenoma-adenocarcinoma transition in cancer

Life of this patent

Abstract

Claims9